340 Results for "

Integrin beta

" in MedChemExpress (MCE) Product Catalog:
Products (340)

340 Results for "Integrin beta" in MCE Product Catalog:

75
75 Publications Verification
Cat. No.: HY-16141
CAS No.: 188968-51-6
Synonyms: EMD 121974
Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors .
loading...
    loading...
75
75 Publications Verification
Cat. No.: HY-16143
CAS No.: 199807-35-7
Synonyms: EMD 121974 TFA
Cilengitide TFA (EMD 121974 TFA) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide TFA inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide TFA inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide TFA can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors .
loading...
    loading...
32
32 Cited Publications
Cat. No.: HY-P0023
CAS No.: 161552-03-0
Target:  

Integrin

Research Areas:  

Cancer

Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM. Cyclo(-RGDfK) potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface .
loading...
    loading...
32
32 Cited Publications
Cat. No.: HY-P0023A
CAS No.: 500577-51-5
Target:  

Integrin

Research Areas:  

Cancer

Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM . Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface .
loading...
    loading...
19
19 Cited Publications
Cat. No.: HY-100506
CAS No.: 1320346-97-1
Purity:  99.43%
Target:  

Integrin

Research Areas:  

Cancer

GLPG0187 is a broad spectrum integrin receptor antagonist with antitumor activity; inhibits αvβ1-integrin with an IC50 of 1.3 nM . GLPG0187 inhibits migrasome biogenesis without cytotoxicity .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-13535A
CAS No.: 904763-27-5
Purity:  99.04%
Synonyms: ATN-161 TFA salt
Target:  

Integrin

Research Areas:  

Cancer

ATN-161 trifluoroacetate salt is a novel integrin α5β1 antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model.
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-13535
CAS No.: 262438-43-7
ATN-161 is an antagonist of α5β1 integrin and αvβ3 integrin, as well as an inhibitor of fibrosis, an inhibitor of oxidative stress, a tight junction stabilizer, a mitochondrial integrity protector, an angiogenesis inhibitor and an antiviral agent. ATN-161 inhibits NLRP3, MAPK, and ROS. ATN-161 protects mice from SARS-CoV-2 infection . ATN-161 reduces infarct volume, alleviates edema, decreases immune cell infiltration, reduces the area of choroidal neovascularization lesions, lowers tumor microvessel density and viral load. ATN-161 can be used in research related to ischemic stroke, choroidal neovascularization, breast cancer, coronavirus disease 2019 (COVID-19), and liver metastasis of colorectal cancer .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-18676
CAS No.: 2070015-22-2
Research Areas:  

Cancer

OSU-T315 (ILK-IN-1) is a small Integrin-linked kinase (ILK) inhibitor with an IC50 of 0.6 μM, inhibiting PI3K/AKT signaling by dephosphorylation of AKT-Ser473 and other ILK targets (GSK-3β and myosin light chain) . OSU-T315 abrogates AKT activation by impeding AKT localization in lipid rafts and triggers caspase-dependent apoptosis in an ILK-independent manner . OSU-T315 causes cell death through apoptosis and autophagy .
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-18644
CAS No.: 1564286-55-0
Target:  

Integrin

Research Areas:  

Cancer

CWHM-12 is a potent inhibitor of αV integrins with IC50s of 0.2, 0.8, 1.5, and 1.8 nM for αvβ8, αvβ3, αvβ6, and αvβ1.
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-P1740
CAS No.: 114681-65-1
Target:  

Integrin Apoptosis Caspase

Research Areas:  

Inflammation/Immunology

RGD peptide (GRGDNP) is an inhibitor of integrin-ligand interactions. RGD peptide (GRGDNP) competitively inhibits α5β1 binding with extracellular matrice (ECM). RGD peptide (GRGDNP) promotes apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing. RGD peptide (GRGDNP) plays an important role in cell adhesion, migration, growth, and differentiation .
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-P1740A
Target:  

Integrin Apoptosis

Research Areas:  

Inflammation/Immunology Cancer

RGD peptide (GRGDNP) TFA is an inhibitor of integrin-ligand interactions. RGD peptide (GRGDNP) TFA competitively inhibits α5β1 binding with extracellular matrice (ECM). RGD peptide (GRGDNP) TFA promotes apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing. RGD peptide (GRGDNP) TFA plays an important role in cell adhesion, migration, growth, and differentiation .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-15102
CAS No.: 227963-15-7
Purity:  99.50%
Synonyms: L-000845704
Target:  

Integrin

Research Areas:  

Inflammation/Immunology Cancer

MK-0429 (L-000845704) is an orally active, potent, selective and nonpeptide pan-integrin antagonist with IC50 values of 1.6 nM, 2.8 nM, 0.1 nM, 0.7 nM, 0.5 nM and 12.2 nM for αvβ1, αvβ3, αvβ5, αvβ6, αvβ8 and α5β1, respectively .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-100445A
Purity:  98.28%
Target:  

Integrin

Research Areas:  

Cardiovascular Disease Cancer

αvβ1 integrin-IN-1 TFA (Compound C8) is a potent and selective αvβ1 integrin inhibitor with an IC50 of 0.63 nM. Antifibrotic effects .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-100445
CAS No.: 1689540-62-2
Purity:  99.51%
Target:  

Integrin

Research Areas:  

Cardiovascular Disease Cancer

αvβ1 integrin-IN-1 (Compound C8) is a potent and selective αvβ1 integrin inhibitor with an IC50 of 0.63 nM. Antifibrotic effects .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-13306
CAS No.: 1228445-38-2
Purity:  99.71%
Target:  

Integrin

Research Areas:  

Metabolic Disease

Pyrintegrin is an β1-integrin agonist and a 2,4-disubstituted pyrimidine that promotes embryonic stem cells survival. Pyrintegrin enhances cell-extracellular matrix (ECM) adhesion-mediated integrin signaling. Pyrintegrin can be used as a podocyte-protective agent and has robustly adipogenic .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-14951
CAS No.: 402567-16-2
Purity:  99.75%
Synonyms: SB 683699
Target:  

Integrin

Research Areas:  

Neurological Disease

Firategrast (SB 683699) is an orally active and specific α4β1/α4β7 integrin antagonist. Firategrast reduces trafficking of lymphocytes into the central nervous system (CNS) and decreases multiple sclerosis (MS) activity .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-15770
CAS No.: 232271-19-1
Purity:  98.06%
Target:  

Integrin

Research Areas:  

Inflammation/Immunology

TR-14035 is a orally active dual α4β74β1 integrin antagonist, with IC50 s of 7 nM and 87 nM for α4β7 and α4β1, respectively. TR-14035 can be used for the research of inflammation and autoimmune diseases .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-100563A
CAS No.: 217099-14-4
Purity:  99.83%
Target:  

Integrin

Research Areas:  

Cancer

Cyclo(RGDyK) is a potent and selective αVβ3 integrin inhibitor with an IC50 of 20 nM.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-100563
CAS No.: 250612-42-1
Purity:  99.92%
Target:  

Integrin

Research Areas:  

Cancer

Cyclo(RGDyK) trifluoroacetate is a potent and selective αVβ3 integrin inhibitor with an IC50 of 20 nM.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-P1408
CAS No.: 404882-00-4
Target:  

Integrin VEGFR

Research Areas:  

Cancer

Obtustatin is a non-RGD disintegrin consisting of 41 residues. Obtustatin inhibits the adhesion of α1β1 integrin to type IV Collagen (HY-NP003), blocks α1β1 integrin signaling in endothelial cells, and suppresses FGF2-induced angiogenesis. Obtustatin inhibits tumor progression in mouse models and upregulates VEGF expression in sarcoma-bearing mice. Obtustatin can be used in research related to Lewis lung carcinoma and S-180 sarcoma .
loading...
    loading...